The Barcelona-based company said the funds will support completion of the ongoing Athena pivotal IDE study, a prospective, randomized, 327-subject trial intended to evaluate the safety and performance of the ANA Funnel Catheter.
Omega Funds led the round, along with new investor Spain’s Co-investment fund (FOCO, which is managed by COFIDES). There was also continued participation from Asabys Sabadell Asabys II), Ysios Capital, and CDTI (through its SICC Innvierte).
Anaconda’s proprietary Funnel Catheter platform is meant to improve clot capture, reduce embolic complications and maximize brain reperfusion — overcoming persistent challenges in the treatment of ischemic strokes. The company secured a CE mark last year for the ANA5 funnel catheter, and it has established a production facility on the edge of Barcelona.
“This latest funding round allows us to further advance our work in the acute treatment of those suffering a stroke, with the goal of reducing disability and death caused by large vessel occlusive disease,” Anaconda Biomed CEO Trent Reutiman said in a Sept. 23 news release. “The support of this leading group of investors reflects the growing confidence in our technology platform, and the funds raised will ensure that the company has the required resources to complete the clinical and regulatory requirements.”
Claudio Nessi, managing director of Omega Funds, said: “Anaconda is bringing a next- generation solution to the large and growing ischemic stroke market. For millions of patients around the world, its portfolio of products offers hope for better treatment outcomes. With a very strong team, led by Trent Reutiman, we believe that Anaconda has the resources and unique technology to establish itself in the very active interventional eurovascular device market.”
